Invizyne Technologies (IZTC) Competitors $10.32 -0.18 (-1.71%) As of 06/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. TNXP, INZY, NGNE, TVRD, CADL, PVLA, CMPS, YMAB, DBVT, and CGCShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Tonix Pharmaceuticals (TNXP), Inozyme Pharma (INZY), Neurogene (NGNE), Tvardi Therapeutics (TVRD), Candel Therapeutics (CADL), Palvella Therapeutics (PVLA), COMPASS Pathways (CMPS), Y-mAbs Therapeutics (YMAB), DBV Technologies (DBVT), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Its Competitors Tonix Pharmaceuticals Inozyme Pharma Neurogene Tvardi Therapeutics Candel Therapeutics Palvella Therapeutics COMPASS Pathways Y-mAbs Therapeutics DBV Technologies Canopy Growth Tonix Pharmaceuticals (NASDAQ:TNXP) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability. Is TNXP or IZTC more profitable? Invizyne Technologies has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Invizyne Technologies' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,313.87% -120.96% -101.28% Invizyne Technologies N/A N/A N/A Do institutionals & insiders have more ownership in TNXP or IZTC? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, TNXP or IZTC? Invizyne Technologies has lower revenue, but higher earnings than Tonix Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M24.79-$130.04M-$1.96 thousand-0.02Invizyne TechnologiesN/AN/AN/AN/AN/A Does the media favor TNXP or IZTC? In the previous week, Tonix Pharmaceuticals had 7 more articles in the media than Invizyne Technologies. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 0 mentions for Invizyne Technologies. Tonix Pharmaceuticals' average media sentiment score of 0.63 beat Invizyne Technologies' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Tonix Pharmaceuticals Positive Invizyne Technologies Neutral Do analysts recommend TNXP or IZTC? Tonix Pharmaceuticals currently has a consensus target price of $585.00, suggesting a potential upside of 1,621.09%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Tonix Pharmaceuticals is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryTonix Pharmaceuticals beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.52M$1.35B$5.21B$8.75BDividend YieldN/A1.04%5.38%4.22%P/E RatioN/A3.2525.1019.38Price / SalesN/A250.38397.10117.31Price / CashN/A34.7935.5255.95Price / BookN/A6.138.005.51Net IncomeN/A-$76.77M$3.14B$248.27M7 Day Performance-19.44%0.26%0.89%0.76%1 Month Performance-30.74%0.38%5.18%4.44%1 Year PerformanceN/A11.86%37.53%16.92% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$10.32-1.7%N/AN/A$64.52MN/A0.0029TNXPTonix Pharmaceuticals3.1008 of 5 stars$35.21+7.4%$585.00+1,561.5%-70.0%$259.15M$10.09M-0.0250INZYInozyme Pharma2.6785 of 5 stars$4.00+0.3%$11.75+193.8%-10.9%$258.24MN/A-2.3750NGNENeurogene3.419 of 5 stars$17.80+3.4%$46.17+159.4%-45.8%$253.83M$930K-4.0990TVRDTvardi TherapeuticsN/A$27.02+6.5%$71.50+164.6%N/A$252.91M$7.14M0.0080CADLCandel Therapeutics2.4803 of 5 stars$4.94+5.8%$21.00+325.1%-21.1%$247.49M$120K-3.6960News CoveragePVLAPalvella Therapeutics3.1885 of 5 stars$21.86-3.0%$46.29+111.7%N/A$241.77M$42.81M-1.81N/ANews CoveragePositive NewsCMPSCOMPASS Pathways2.2011 of 5 stars$2.58+9.8%$17.00+558.9%-59.8%$241.39MN/A-1.30120News CoverageAnalyst ForecastOptions VolumeHigh Trading VolumeYMABY-mAbs Therapeutics2.7517 of 5 stars$5.33+12.9%$15.60+192.7%-57.6%$241.34M$87.68M-8.33150DBVTDBV Technologies3.4563 of 5 stars$8.56flat$14.75+72.3%+78.9%$234.46M$4.15M-1.7480News CoverageGap UpCGCCanopy Growth2.4532 of 5 stars$1.26+5.9%$2.00+58.7%-82.1%$231.68M$225.65M-0.313,150 Related Companies and Tools Related Companies Tonix Pharmaceuticals Alternatives Inozyme Pharma Alternatives Neurogene Alternatives Tvardi Therapeutics Alternatives Candel Therapeutics Alternatives Palvella Therapeutics Alternatives COMPASS Pathways Alternatives Y-mAbs Therapeutics Alternatives DBV Technologies Alternatives Canopy Growth Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IZTC Stock Free IZTC Stock Alerts